Amyloid blood biomarker of Alzheimer’s disease using single-molecule detection

Purpose and goal:

The project has delivered the results that we planned and most of the objective we set up from the beginning have been achieved. In particular, the portable demonstrator of the plug-and-play benchtop instrument for amyloid detection in biological fluids and peptide/protein medications by massively parallel fluorescence intensity fluctuation analysis has been successfully designed and assembled. In addition, relevant documentation has been created.

Expected results and effects:

The MVP version of our instrument developed in this project is ready for verification and preliminary validation in relevant environments, which is our next objective. This brings us one step closer to the development of an instrument that complies with regulatory eligibility requirements for In Vitro Diagnostic Devices (IVDD), which can be used for amyloid detection in body fluids to diagnose amyloid diseases.

Approach and implementation:

The project developed largely according to plan and most of the objectives set from the beginning were met. However, there was an unexpected delay due to the long delivery time of a critical component, which affected the schedule. Despite this external factor, no other unexpected problems hindered the progress of the project. Collaboration within the project team worked as planned, and communication was efficient, helping to resolve most of the challenges that arose.